Ltd Announces the Appointment of Dr Richard J. White as Chairman of
the Board of Directors
UK, 23 February 2010
- F2G Limited, the Manchester UK based antifungal drug discovery and
development company, today announced the appointment of Dr Richard J.
White as Chairman of the Company's Board of Directors. Dr White has
served as a non-executive director of F2G Ltd since April 2006.
F2G also announced the appointment of a new non-executive director,
Dr Sten Verland of Sunstone Capital A/S.
"I congratulate Richard on his appointment as Chairman" said
Shane M. Kelly, Chief Executive of F2G Ltd. "Richard has a wealth
of experience in infectious disease drug discovery gained within Biotech
and Pharma. He has been a tremendous asset to the Company during his
time on the Board and I look forward to working with him towards the
further development of F2G Ltd. The Board also welcomes Dr Sten Verland,
whose proven expertise in building successful businesses will be a valuable
addition to the team."
Dr Richard J. White commented "This an exciting time for F2G as
our lead program progresses to clinical testing and I eagerly anticipate
working closely with the other Board members".
Based in Manchester, UK, F2G Ltd is dedicated to the discovery and development
of new and clinically superior drug classes to treat life-threatening
systemic fungal infections in at-risk patient populations. The antifungal
market is currently estimated at over 6 billion dollars annually and
is growing steadily year on year. Market growth is expected to increase
with the emergence of new clinical indications in allergies and asthma.
The company has impressive internal capabilities, employing a core team
of scientists with a unique understanding of the antifungal arena, supported
by an experienced management team. F2G operates a flexible business
model, building value through the development of a balanced portfolio
of antifungal assets across multiple validated TPPs.
For more information visit www.f2g.com
Chief Executive Officer
Tel: (+44) 0161 785 1271
Fax: (+44) 0161 785 1273